NCT01907113View on ClinicalTrials.gov

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BI 10773 in Type II Diabetes Patients With Different Degrees of Renal Impairment

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

BI 10773

oral administration

DRUG

BI 10773

oral administration

DRUG

BI 10773

oral administration

DRUG

BI 10773

oral administration

DRUG

BI 10773

oral administration

Trial Locations (2)

Unknown

1245.12.1 Boehringer Ingelheim Investigational Site, Kiel

1245.12.2 Boehringer Ingelheim Investigational Site, Neuss

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY